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Abstract: Herbal supplements are increasingly used in psychiatric practice. Our epidemiological
study has identified several herbal preparations associated with adverse outcomes of antipsychotic
therapy. In this study, we evaluated the in vitro effects of four herbal preparations—Radix Rehmanniae
(RR), Fructus Schisandrae (FS), Radix Bupleuri (RB) and Fructus Gardeniae (FG)—on cytochrome P450s
(CYPs) involved in the metabolism of clozapine in human liver microsomes (HLMs) and recombinant
human cytochrome P450 enzymes (rCYPs). N-desmethylclozapine and clozapine N-oxide, two major
metabolites of clozapine, were measured using high-performance liquid chromatography (HPLC). FG,
RR and RB showed negligible inhibitory effects in both in vitro systems, with estimated half-maximal
inhibitory concentrations (IC50) and apparent inhibitory constant values (Ki) greater than 1 mg/mL
(raw material), suggesting that minimal metabolic interaction occurs when these preparations are
used concomitantly with clozapine. The FS extract affected CYP activity with varying potency; its
effect on CYP 3A4-catalyzed clozapine oxidation was relatively strong (Ki: 0.11 mg/mL). Overall, the
weak-to-moderate inhibitory effect of FS on in vitro clozapine metabolism indicated its potential role
in herb-drug interaction in practice.
Keywords: herb-drug interaction; clozapine; human liver microsomes; recombinant CYPs
1. Introduction
According to the World Health Organization, traditional medicine meets the primary healthcare
needs of 80% of the population in undeveloped regions [1]. As herbal products are obtained
from natural sources, they are usually regarded as safe for human consumption. Combinations
of herbal and conventional medication are increasingly prescribed to provide synergistic/additive
therapeutic efficacy or to reduce side effects induced by synthetic drugs. However, concerns about
herb-drug interactions (HDI) have increased along with the growth of polypharmacy. In a previous
epidemiological study [2], we found that 36.4% of the schizophrenic patients in our sample had been
prescribed herbal medicines in combination with antipsychotics. A small, but significant proportion of
these patients experienced more negative clinical consequences than those who received antipsychotics
only, suggesting the potential existence of HDI.
Clozapine (CLZ), an antipsychotic medication, is prescribed to a large proportion of schizophrenia
patients and is the preferred first-line treatment for schizophrenia in China [3]. It is also the
medication most commonly prescribed to refractory-schizophrenia patients worldwide [4]. In this
study, we measured the kinetic effects on CLZ metabolism of four herbal medicines: Radix Rehmanniae
(Rehmannia glutinosa Libosch; RR; Di-Huang), Fructus Schisandrae (Schisandra chinensis Baill;
FS; Wu-Wei-Zi), Radix Bupleuri (Bupleurum chinense DC.; RB; Chai-Hu) and Fructus Gardeniae
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(Gardenia jasminoides Ellis; FG; Zhi-Zi). These four medicines were selected due to their extensive
clinical use and pharmacological benefits in the treatment of psychotic disorders [5–7] and their
significant observed correlation with adverse clinical outcomes when concomitantly consumed with
antipsychotic agents [2].
Natural herbs and synthetic pharmaceuticals always share the same metabolizing enzymes before
excretion from the human body. The cytochrome P450 (CYP) enzyme system is responsible for the
biotransformation of more than 90% of the drugs on the market [8]. Most CYP enzymes are found in
the liver, which serves as the primary site for the metabolism of psychotropic agents [9]. As previously
reported, CLZ is catalyzed to two major metabolites by a group of CYPs, principally CYP 1A2, CYP
3A4, CYP 2D6 and CYP 2C19 [10], at the hepatic level. CYP 1A2 plays a major role in mediating the
formation of N-demethyl CLZ (norCLZ), while both CYP 2D6 and CYP 2C19 contribute minorly, and
CLZ N-oxide is primarily catalyzed by CYP 3A4 [11]. Research has shown that the alteration of CYP
enzyme activities by inhibitors or inducers plays an important role in the mechanism of HDI [12].
So far, little research was focused on the pharmacokinetic interaction between herbal medicines and
antipsychotics. Such HDI becomes critical as psychiatric patients would have a long-period medication,
but limited information could be found for guidance to the clinicians. Therefore, characterizing the
influence of the above four herbal drugs on the CYP activities involved in CLZ metabolism is of great
clinical significance. In this study, we performed kinetic analysis to investigate the effects of RB, RR,
FG and FS on the metabolism of clozapine in human liver microsomes (HLMs) and recombinant CYP
enzymes (rCYPs).
2. Results
2.1. Quantitative Analysis of Major Bioactive Constituents of Herbs
A marker-based approach was used to standardize the herbal extracts. Specific HPLC methods
based on the previous reports [13–16] were developed to measure two marker components from each
of the four herbal preparations. Before each injection, a mobile phase that was the same as the initial
condition of the gradient elution would last for 10 min for equilibrium. The content of the eight
bioactive markers is summarized in Table 1. Quantitative analysis revealed that all of the specific
constituents were well characterized, with the exception of saikosaponin D from the RB extract, which
was found to be below the detection level.
Table 1. Measurement of bioactive constituents of Radix Rehmanniae (RR), Fructus Schisandrae (FS),
Radix Bupleuri (RB) and Fructus Gardeniae (FG).
Herb MobilePhase Conditions
a λmax




0–12 min, 1%–5%; 12–15 min, 5%–10%; 15–18 min,
10%–60%; 18–20 min, 60%–80%; 20–25 min, 80%–1% 210
Catalpol 5.60 ˘ 0.28
Acteoside 1.59 ˘ 0.24
FS MeOH/H2O 0–25 min, 65% 215
Schisandrin 0.65 ˘ 0.05
Schisandrol B 1.84 ˘ 0.37
RB ACN/0.1%
formic acid
0–3 min, 30%–40%; 3–9 min, 40%–60%; 9–20 min,
60%–80%; 20–22 min, 80%–30% 210




0–10 min, 5%–10%; 10–20 min, 10%–50%; 20–22 min,
50%–80%; 22–23 min, 80%; 23–24 min, 80%–5%
240 Geniposide 48.3 ˘ 12.0
210 Gardenin A 0.32 ˘ 0.02
a Chromatography conditions expressed as organic-phase ratio. b Data expressed in the form of the
mean ˘ standard deviation (SD) mg per g raw materials.
2.2. Inhibition Analysis in Pooled HLMs
The effects of the four herbal extracts on the formation of norCLZ and CLZ N-oxide in pooled
HLMs were thoroughly examined. Michaelis–Menten constant (Km) values of 58.1 µM for CLZ
demethylation and 34.3 µM for oxidation were obtained from pilot experiments, with maximal-velocity
(Vmax) values of approximately 687 and 915 pmol/min per milligram of protein, respectively. We then
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used a substrate concentration of 50 µM CLZ in the following dose-response experiments involving
herbs. The IC50 values obtained for the four herbal extracts are indicated in Table 2 and Figure 1. The
RB and RR preparations were found to have an equivalent inhibitory effect on CLZ demethylation
and the formation of oxidative products, with IC50 values of approximately 8.8 mg/mL for RB and
1.6 mg/mL for RR. FS exhibited distinct suppression effects on the formation of two metabolites, with
IC50 values of 0.40 mg/mL for norCLZ and 0.18 mg/mL for CLZ N-oxide. FG varied dramatically in
its inhibitory effect on the formation of norCLZ (10.17 mg/mL) and CLZ N-oxide (2.03 mg/mL).
Table 2. Potency of inhibitory effects of Radix Rehmanniae (RR), Fructus Schisandrae (FS), Radix Bupleuri
(RB) and Fructus Gardeniae (FG) on CLZ metabolism in human liver microsomes a.
Metabolites Km (µM)
Vmax (pmol/min/mg Protein) IC50 (mg/mL)
RR FS RB FG
norCLZ 58.1 ˘ 2.46 687 ˘ 18.8 1.46 ˘ 0.06 0.40 ˘ 0.10 8.77 ˘ 0.60 10.2 ˘ 2.41
CLZ N-oxide 34.3 ˘ 1.25 915 ˘ 36.7 1.78 ˘ 0.05 0.18 ˘ 0.00 8.82 ˘ 0.84 2.03 ˘ 0.16
a Data expressed in the form of the mean ˘ standard error of mean (SEM) (n = 3).
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RR and RB weakly inhibited the formation of both norCLZ and CLZ N-oxide by all four of the CYPs, 
with inhibitory constant (Ki) values of 3.00–10.8 and 3.90–13.8 mg/mL, respectively. FS was found to 
have a greater inhibitory potential: the herb moderately inhibited CYP activity, with Ki values ranging 
from 0.11–1.05 mg/mL. FG weakly suppressed the demethylation of CLZ catalyzed by CYP 1A2, CYP 
2C19, CYP 2D6 and CYP 3A4 (Ki: 2.23–8.80 mg/mL), but exhibited a slightly more potent inhibitory 
effect on the CYP 3A4-mediated formation of CLZ N-oxide, with a Ki of 0.85 mg/mL. 
Figure 1. Inhibition of CLZ metabolism in HLMs by various concentrations of Radix Rehmanniae
(RR), Fructus Schisandrae (FS), Radix Bupleuri (RB) and Fructus Gardeniae (FG). Experiments conducted
in triplicate.
2.3. Inhibition Analysis with Recombinant CYPs
The inhibitory potency of the four herbs on the CYP isoforms (CYP 1A2, 2C19, 2D6 and 3A4)
involved in CLZ metabolism was further examined in rCYPs. The results are summarized in Table 3
and Figure 2. Km and Vmax values for the individual isoforms involved in CLZ metabolism are listed.
The inhibition modes of the four herbs for individual isoforms are indicated in respective Dixon plots.
RR and RB weakly inhibited th formation of both norCLZ an CLZ N-oxide by all four of the CYPs,
with inhibitory constant (Ki) values of 3.00–10.8 an 3.90–13.8 mg/mL, respectively. FS was found to
have a greater inhibitory potential: the herb moderately inhibited CYP activity, with Ki values ranging
from 0.11–1.05 mg/mL. FG weakly suppressed the demethylation of CLZ catalyzed by CYP 1A2, CYP
2C19, CYP 2D6 and CYP 3A4 (Ki: 2.23–8.80 mg/mL), but exhibited a slightly more potent inhibitory
effect on the CYP 3A4-mediated formation of CLZ N-oxide, with a Ki of 0.85 mg/mL.
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Table 3. Potency of the inhibitory effects of Radix Rehmanniae (RR), Fructus Schisandrae (FS),
Radix Bupleuri (RB) and Fructus Gardeniae (FG) on CLZ metabolism in human recombinant cytochrome
P450s a.




RR FS RB FG
1A2 norCLZ 83.9 ˘12.1 30.9 ˘ 3.90 10.8 ˘ 1.32 0.97 ˘ 0.12 11.5 ˘ 1.40 8.80 ˘ 0.51
2C19 norCLZ 23.8 ˘ 6.91 33.9 ˘ 10.6 3.00 ˘ 0.78 0.21 ˘ 0.02 3.90 ˘ 0.52 2.23 ˘ 0.07
2D6 norCLZ 12.2 ˘ 0.70 49.3 ˘ 2.12 6.00 ˘ 0.47 1.05 ˘ 0.08 13.8 ˘ 0.18 7.77 ˘ 0.59
3A4 norCLZ 66. 5 ˘ 12.1 21.2 ˘ 2.84 7.43 ˘ 0.73 0.22 ˘ 0.04 5.37 ˘ 0.73 4.83 ˘ 0.19
3A4 CLZ N-oxide 21.9 ˘ 4.52 34.9 ˘ 3.94 5.83 ˘ 0.61 0.11 ˘ 0.00 4.47 ˘ 0.78 0.85 ˘ 0.14
a Data expressed in the form of the mean ˘ SEM (n = 3).
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Figure 2. Dixon plot analysis of CLZ demethylation to norCLZ catalyzed by CYP 1A2 (A); CYP
2C19 (B); CYP 2D6 (C); CYP 3A4 (D) and CLZ oxidation to CLZ N-oxide by CYP 3A4 (E) with
various concentrations of Radix Rehmanniae (RR), Fructus Schisandrae (FS), Radix Bupleuri (RB) and
Fructus Gardeniae (FG) at fixed CLZ concentrations.
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3. Discussion
Herbal products are popular worldwide, especially as complementary and alternative forms of
medicine. This study investigated the metabolic influence of four commonly-used herbal medicines
on clozapine metabolism in HLMs and recombinant CYP enzymes. First, the major constituents of
the herbal preparations under study were determined. It is well known that the quality control of
herbal medicines relies on the identification and quantification of their chemical constituents, since the
contents of bioactive chemicals correlate with herbal pharmacological outcomes and clinical value.
In our experiment, two components of each herb were selected as markers to perform a valid and
quick detection analysis. The data obtained from the extracts were in line with the findings of previous
reports [14,17–19]. Saikosaponin D was found to be under the detection limit (0.07 mg/mL), due to the
water extraction process. Therefore, the prepared herbal extracts were found to be highly suitable for
use in our experimental study.
The results for HLMs, which contain abundant CYP enzymes, are shown in Figure 1 and Table 2.
These findings suggest that RB, RR and FG played only a minor role in reducing the formation of CLZ
metabolites. However, FS had a weak to moderate suppression effect on CLZ biotransformation; its
effect on oxidative metabolism was especially strong. The distinct activities were also shown in the
experiment involving FG, whose IC50 value for CLZ demethylation was approximately five-times
greater than that for oxidation. The explanation may be attributed to the involvement of diverse CYPs
in various metabolic pathways. To address this issue, the effects of the herbal extracts were further
evaluated by examining the inhibition of individual CYP isoforms, as the “apparent” Ki value offers
a better measure of the interaction of an inhibitor with a particular enzyme [20]. The results were
similar to those of the HLM experiments (Figure 2 and Table 3). RB and RR had a negligible influence
on all of the CYP isoforms. The FG extract exhibited a very weak inhibitory effect on demethylation
induced by the CYP isoforms 1A2, 2C19, 2D6 and 3A4 (Ki values of 2.23–8.80 mg/mL). However, FG
was found to have a greater potential to inhibit CYP 3A4-induced oxidation, with an estimated Ki
value of 0.85 mg/mL. Consistent results were also obtained in the experiments involving FS. CYP
3A4-mediated CLZ oxidation was found to be sensitive to the addition of FS (Ki value of 0.11 mg/mL),
unlike CLZ demethylation via multiple isoforms (Ki values from 0.21–1.05 mg/mL). Our results are
in accordance with those published, finding that CYP 3A4 activity was noticeably inhibited by FG
and FS, either extract or their certain components [21–23]. In this study, we make the novel proposal
that the inhibition of CYP 3A4 activities by FG and FS is metabolic pathway dependent. This partly
supports Mooiman’s [24] argument that at least two substrates must be tested in any given in vitro
study to prevent inter-laboratory differences and confirm the effects of inhibitors on CYP activity.
Although the results of our study suggest that the metabolism of CLZ was moderately inhibited
by FS, it is important to note that these in vitro findings may not be replicable in a clinical environment.
Iwata [25] reported that a variety of constituents of FS exhibited in vitro inhibitory effects on CYP
3A4 in human P450 isoforms. In particular, gomisin C was found to be a more potent inhibitor of
CYP 3A4 than ketoconazole. In a rat model, Lai [26] and Su [27] confirmed that a single dose of FS
inhibited CYP 1A2 and CYP 3A4 and induced CYP 2E1. However, Mu [28] found that the long-term
use of FS elevated the expression of drug-metabolizing enzymes, such as CYP 3A and CYP 2C, by
activating the xenobiotic orphan nuclear receptor pregnane X receptor, ultimately accelerating the
biotransformation of certain drugs. These inconsistent results reflect the complexity of in vivo settings
for drug metabolism.
To conclude, the relatively high Ki values obtained for RB, FG and RR suggest that these herbs
have little potential for direct pharmacokinetic interaction with CLZ in practice. The adverse clinical
outcomes observed should be attributed primarily to other factors, for instance the therapeutic
predominance of multi-drug regimens rather than single herbs, suggesting potential herb-herb
interaction. FS may affect CLZ blood concentration and increase risk indicated by inhibited
CYP enzymes in vitro. However, more research is needed to accurately determine the in vivo
pharmacokinetic effect of FS on CLZ biotransformation.
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4. Experimental Section
4.1. Drugs and Reagents
CLZ (>99.0% purity), norCLZ (>99.0% purity) and CLZ N-oxide (>99.0% purity) were obtained
from Selleck Chemicals (Houston, TX, USA), Tocris (Bristol, UK) and Enzo Life Sciences, Inc.
(Farmingdale, NY, USA), respectively. The bioactive compounds contained in the four herbal medicines,
saikosaponin A (>98.0% purity), saikosaponin D (>98.0% purity), geniposide (>98.0% purity),
gardenin A (>98.0% purity), catalpol (>98.0% purity), acteoside (>98.0% purity), schisandrin (>98.0%
purity) and schisandrol B (>98.0% purity), were all obtained from Shanghai Yuanye Bio-Technology
Co. Ltd. (Shanghai, China). Pooled HLM from 25 donors (18 males and 7 females) and recombinant
CYP 1A2, CYP 2C19, CYP 2D6 and CYP 3A4 isoforms were purchased from BD Gentest (Woburn, MA,
USA). NADPH tetrasodium salt (>95.0% purity) was purchased from Santa Cruz Biotechnology, Inc.
(Dallas, TX, USA). High-performance liquid chromatography (HPLC)-grade solvents were supplied
by Duksan (Ansan, Korea), and the other analytical reagents used in the study were obtained from
Sigma-Aldrich (St. Louis, MO, USA).
4.2. Herbal Preparation and Quality Determination
The four herbal medicines under study were prepared using the same protocol. The raw materials
for Radix Rehmanniae (RR), Radix Bupleuri (RB), Fructus Schisandrae (FS) and Fructus Gardeniae (FG) were
supplied and deposited by the pharmacy at the School of Chinese Medicine, the University of Hong
Kong. Voucher specimens were identified by Dr. Yan-Bo Zhang at the School of Chinese Medicine,
the University of Hong Kong. As recommended in The Pharmacopoeia of the People’s Republic of China,
water extraction was used to preserve the bioactive constituents [29]. Briefly, the raw materials for
each preparation (1.8 kg) were sliced and broiled, then immersed and boiled in a 10-fold volume of
distilled water for 2 h. This process was repeated twice, as reported in an earlier study [30]. Next,
the solution obtained for each herb was pooled and concentrated to a 1.8-L volume to create a stock
solution of 1 g/mL for further use.
To ensure that the herbal preparations were of a high quality and to prevent variation in their
composition, all of the extracts were prepared individually from the same batch. The content of the
bioactive constituents was measured using reverse-phase HPLC.
4.3. Inhibition Assay in HLMs
First, we determined the concentration of each herbal drug required to inhibit the original enzyme
activity in HLMs by 50% (IC50). CLZ was dissolved in water with 0.05% acetic acid. As reported
in a previous study, incubation time and protein concentration were selected to ensure the linear
formation of norCLZ and CLZ N-oxide [10]. In a pilot study, a Km value of approximately 50 µM
was obtained for CLZ in HLMs and, thus, chosen as the optimal concentration for IC50 determination.
In addition, the linear formation of the two metabolites in terms of incubation time was confirmed
and 15 min for HLM was found with good linearity. Incubations were performed in triplicate in
polypropylene tubes. The typical system contained 100 mM potassium phosphate buffer (pH 7.4) and
50 µg of HLMs in a final volume of 100 µL. CLZ and the individual inhibitors, namely RB, RR, FS
and FG, were added to the mixture and placed in a 37 ˝C water bath for 5 min. Next, the reactions
were initiated by adding 1 mM NADPH and terminated by adding 100 µL ice-cold acetonitrile 15 min
later. The samples were centrifuged at 12,000ˆ g for 10 min, and an aliquot (50 µL) of supernatant was
separated for HPLC analysis.
4.4. Inhibition Assay with Recombinantly-Expressed Enzymes
The inhibitory effects of individual herbal preparations on specific CYP enzymes were further
examined in recombinant P450 isoforms. The incubation mixtures contained CYP isoforms
(20 pmol/mL) instead of HLM proteins. The subsequent experimental conditions were similar to those
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for the HLM mixtures. The substrate, CLZ, was added in serial concentrations from 5–50 µM, in the
absence of the herbal extracts and in the presence of the herbal extracts at five serial concentrations
from 0.05–20 mg/mL. The reactions lasted for 15 min each, except the reaction involving CYP 2C19,
which lasted for 30 min. The samples were centrifuged and stored at´80 ˝C to enable the measurement
of norCLZ and CLZ N-oxide.
4.5. Measurement of Individual Herbal Bioactive Constituents and CLZ Metabolites
The samples were chromatographically separated on an ACE5 AQ column (5 mm, 4.6 ˆ 250 mm;
Advanced Chromatography Technologies Ltd., Aberdeen, UK) using a Waters 626 series HPLC system
(Waters, Milford, MA, USA). Different mobile-phase conditions were used to measure the constituents
of the four herbal extracts. Details of the separation methods and the absorbance wavelength applied
are provided in Table 1. To measure the CLZ metabolites, the analytes were separated in a mobile
phase consisting of Solvent A, acetonitrile, and Solvent B, 0.1% (v/v) acetic acid, in water at a flow rate
of 1 mL/min. A gradient elution was used to analyze the CLZ metabolites: 0–18 min, 14%–20% A;
18–30 min, 20%–40% A; 30–35 min, 40%–60% A; 35–40 min, 14% A. The absorbance of norCLZ and
CLZ N-oxide was measured at 240 nm. The precision of norCLZ and CLZ N-oxide was less than 7.0%
and 6.3%, respectively. The accuracy of norCLZ and CLZ N-oxide was within ˘5.9% and ˘10.5%.
All within the acceptable range. The lower limit of quantification of norCLZ was 0.79 µM and 1.67 µM
for CLZ N-oxide. The representative HPLC chromatogram is shown in Supplementary Figure S1.
4.6. Data Analysis
All of the data are represented as the means of triplicate measurements. The Km and Vmax values
for CLZ demethylation and oxidation obtained in the HLM experiments were analyzed using Prism 5
(GraphPad Software Inc., La Jolla, CA, USA). GraFit 5 (Erithacus Software Limited, Surrey, UK) was
used to calculate the IC50 values. The data obtained from the recombinant-enzyme experiments were
analyzed using SigmaPlot software (Systat Software Inc., Chicago, IL, USA). The Ki and the mode of
inhibition were estimated and determined by nonlinear regression analysis of metabolite formation,
with equations for competitive, noncompetitive, mixed and uncompetitive inhibition, respectively. The
goodness of fit was assessed using the lowest Akaike information criterion value. In addition, Dixon
plots were visually inspected to verify the mode of inhibition. Cornish-Bowden plots were applied to
double check.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/
21/5/597/s1.
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